Eravac is an injectable emulsion ready for administration without the need for reconstitution beforehand. Containing 10 vials with individual doses, the new presentation is is indicated for the immunisation of pet rabbits from 30 days of age.
For more information, visit: https://www.hipra.com/portal/en/hipra/animalhealth/products/detail/eravac-pets
Ceva Animal Health has announced that Vetergesic (buprenorphine), its long-lasting analgesic, is now back in stock and on special offer with the rest of the company's analgesic product range.
The company says it has appointed a new, dedicated Vetergesic manufacturing site and increased stock-holding facilities in order to guarantee a continuous long-term supply of the product, which is available in a 10ml vial for use in dogs, cats and horses and a 1ml single dose preparation for cats and dogs.
At the same time, Ceva has launched a spring offer on its entire analgesic product range, which runs till the end of April. For every two packs of Vetergesic, Carprodyl F or Dolagis purchased, veterinary practices will receive one pack free and for every four packs of Meloxidyl purchased, practices will receive one pack free. In addition, practices will be able to take advantage of ongoing rebates through the new CevaSave Rebate Programme.
For further information, contact your local Ceva territory manager, email analgesics-group@ceva.com or call 01494 781510.
Jane (or John) Doe was charged with having stolen midazolam, butorphanol and promethazine hydrochloride from their practice for use other than for veterinary purposes, making false clinical records concerning the use of drugs on their own dogs to disguise the fact that the drugs were instead being used for non-veterinary uses, and drawing up medication taken from the practice into a syringe for the purpose of self-medicating.
In addition, they were charged that their conduct was dishonest.
The Committee found it proven that Jane/John Doe had taken approximately 150 vials of midazolam, 87 ampoules, 112 tablets and one elixir bottle of promethazine hydrocholoride, and 0.2mls of butorphanol together with Iml of midazolam for their dog at a time when their dog was, in fact, dead.
The Committee also found it proven that the defendant had drawn up medication for the purpose of self-medicating, and had created false clinical records.
In deciding the sanction, the Committee concluded that the respondent had abused their position of trust, that their actions were dishonest, prolonged and repeated in nature, and undermined the reputation of the profession as a whole.
Therefore the only appropriate action was removal from the Register.
Unusually, the RCVS did not issue a press release about this case, as it normally does.
There was also a protracted delay between the hearing and the report of the hearing being published on the College website.
Furthermore, when it was finally published, the report had been redacted to remove any reference to the name, gender or location of the respondent.
When asked why, the College said: "Matters of a highly confidential nature arose following the hearing which led to a delay in the decisions being published.
“The decisions have been redacted and we cannot provide the reasons for the redactions as that would necessarily involve disclosure of confidential and personal information.
"However, the circumstances are considered to be exceptional and the College’s decision to make the redactions was only made following very careful consideration of evidence provided to the RCVS.
"The decision has been published on the RCVS website in its redacted form and in view of the timeframe and the circumstances, it has not been considered appropriate to issue a press release.”
CommentThe College will for sure have had very good reasons for redacting the name of the respondent in this case.
One has to assume there must have been a very real threat to the respondent’s life, and under those circumstances, confidentiality is absolutely right and proper.
However, whatever the reason, secrecy is never a good look, especially when it comes in the form of a cape worn by a regulator.
So it is frustrating to hear that the College has again made a rod for its own back, when it could so easily have included a very general one-line explanation for why it felt redaction was necessary, without compromising the individual’s confidentiality.
It would have been enough, for example, just to say that the College felt there was a risk to life. People would accept that.
AceSedate for horses contains 10mg/ml acepromazine as its active ingredient, which the company says means a lower dose volume is required compared to the non-UK licensed equine acepromazine options available.
The dosage of AceSedate is 0.03-0.10 mg per kg bodyweight, however Jurox recommends that the lower end of the dose range is always selected where possible. It can be administered via intramuscular or slow intravenous injection.
AceSedate is supplied in a multidose vial and the shelf life after opening the immediate packaging is 28 days.
Richard Beckwith, country manager of Jurox (UK) Ltd, said: "The launch of AceSedate means injectable acepromazine is now licensed in the UK for horses, giving vets peace-of-mind that a licensed product is now available. It is a welcome addition to our equine anaesthesia, analgesia and sedation portfolio."
For more information, visit: www.jurox.com/uk, contact your local Jurox technical sales representative, telephone the customer services team on 0800 500 3171 or e-mail customerservice@jurox.co.uk.
Charcovet Gel contains 30g of activated charcoal in a 60ml syringe.
Dr John Henderson, Large Animal Product Manager at Forte Healthcare said: “In young animals with digestive disturbances, Charcovet Gel uses the adsorbent properties of activated charcoal to support the gut in a return to normal function.
"The value of using activated charcoal in cases of digestive upset in young animals has long been recognised, but the difficulty and mess involved in mixing such a fine dry powder in water presented considerable usability issues.
"With Charcovet Gel, the appropriate volume of activated charcoal gel is simply selected from the graduated syringe and administered directly into the animal’s mouth.
"Charcovet Gel can be given daily as needed to support the animal during the period of digestive upset.”
Each box of Charcovet Gel contains 12 syringes.
Charcovet Gel is available now from all major veterinary wholesalers, or directly from Forte Healthcare Ltd.
For more information contact your Forte Territory Manager, email enquiries@fortehealthcare.com or visit: https://www.fortehealthcare.com/product/charcovet-gel
Tolracol is a 50mg/ml suspension of toltrazuril which can be used in all three species to prevent coccidiosis infections in youngstock on farms with a history of the disease.
Krka’s head of sales and marketing, Killian Gaffney said: "Coccidiosis can have a devastating impact on young animals, resulting in ill-thrift, weight loss and potentially death, making its prevention a vital component of herd or flock management.
"Importantly, this is a tri-licence single dose product which requires vet prescription. The involvement of the vet in prescribing coccidiostats is important as their use should be part of a whole management approach to prevention."
Krka says Tolracol should be used ahead of the peak infection period on farms with a pre-existing coccidiosis problem, with it recommended for use in neonatal pigs at three to five days old and as soon as required in calves and lambs.
Mr Gaffney added: "This product has been proven in trials and offers a cost-effective option for farmers, it is also easily administered which farmers will find attractive. Krka is launching a new farmer campaign to support Tolracol.
"With lambing and spring calving now taking place across the country vets are likely to be asked in the coming weeks and months about coccidiosis prevention. Tolracol provides another valuable tool in the armoury when it comes to preventing this nasty condition and should be considered as a first-choice product."
For more information, see the SPC or contact Krka UK Limited on +44 (0) 2071 646 156.
Zoetis has announced the launch of Zulvac SBV, a new Schmallenberg vaccine licensed for use in cattle and sheep in two doses at a three week interval, the second at least two weeks before mating.
Zulvac SBV is licensed for use in cattle and sheep in two doses at a three week interval, the second at least two weeks before mating.
Duration of immunity is six months in cattle and seven in sheep. At the recommended vaccination timing, this covers the window of susceptibility during pregnancy; in sheep from day 28 to 56, and days 70 to 150 in cattle. Animals infected during these periods are at risk of malformed offspring and subsequent stillbirth.
The company says vaccination combined with insecticidal measures to control the midge vector remains the most effective way of protecting the population1 and ensuring a more unified level of immunity.
Zoetis vet Carolyn Hogan said: "Although SBV is now considered to be an enzootic pathogen in England and Wales, there is plenty of evidence that seroprevalence at farm level – particularly on sheep farms - varies. As immunity wanes, the proportion of herds and flocks naïve to SBV and at risk via introduction of naïve replacements increases. So the risk of reinfection in assumed enzootic areas is potentially underestimated2.
"Culicoides midges, the SBV vector, are widespread in Europe and move easily between farms and regions, allowing rapid spread of infection."
Carolyn says that whilst there have been no confirmed diagnoses of congenital abnormalities in calves or lambs from APHA in 2014 or 2015, unconfirmed anecdotal cases have been reported.
"We do not know whether our ruminant population is immune or susceptible and neither do we know if another SBV challenge will appear. Vaccination remains the most effective way of ensuring valuable livestock are protected."
Supplies are available immediately.
References
Norbrook Laboratories has launched Noroseal, a new teat sealant containing a unique anti-infective ingredient.
The company says that Noroseal, a 2.6g intramammary suspension, is the only teat sealant in the market-place in Europe to contain a PVP-Iodine excipient.
Dr Barry McInerney MVB, MRCVS, PhD, Norbrook GB Veterinary Advisor said: "Noroseal, with its unique formulation, offers vets a proven barrier against intramammary infections during the dry period.
"New bacterial infections occur most often during the first three weeks of drying off because the cow's natural keratin plug is not completely formed. Indeed, approximately 50% of teat canals are still open for up to seven days after drying off. Noroseal Teat Sealant will mimic the cow's keratin teat barrier offering immediate protection against infection. Additionally, the anti-infective ingredient, PVP-Iodine, complements the effectiveness of the teat-sealant components in the teat canal barrier."
Norbrook says that the estimated annual cost of mastitis to the UK dairy industry is in excess of £168M with a single case of clinical mastitis costing farmers approximately £178.00 per cow.
Dr McInerney added: "Clinical mastitis is a costly business but one that can be avoided if timely action is taken. There are various treatments available for dealing with mastitis but studies have shown that the risk of clinical mastitis may be reduced by up to 50% by using a combination of teat sealant and dry cow intramammary therapy. Noroseal is therefore an ideal combination with Norbrook's dry cow therapies such as Noroclox DC, Bovaclox DC Xtra and Bovaclox DC."
Noroseal is available in packs of 24 or buckets of 120 units. A range of promotional material is also available to veterinary practices via the Norbrook Sales Team.
In next year's election, there are three places on Council for elected veterinary surgeons, with successful candidates serving four-year terms.
The nomination period runs until 5pm on Friday 31 January 2020. In order to stand, candidates need to complete a nomination form, submit a short biography and personal statement and supply a high resolution digital photo.
Each candidate also needs to have two nominators who need to be veterinary surgeons who are on the RCVS Register but are not current RCVS Council members.
Eleanor Ferguson, RCVS Registrar and Returning Officer said: "As always, we would encourage those who are interested in having their say in some of the key debates in the regulatory sphere, such as our under care review, our policies around the impact of Brexit and our vision for new veterinary legislation, to become a candidate.
"RCVS Council is at its best when it encompasses a broad range of perspectives, experiences and knowledge, and so we encourage people from all areas of veterinary life and all levels of experience to put themselves forward and share their expertise and insight."
Nomination forms, guidance notes and frequently asked questions for prospective RCVS Council candidates can be found at www.rcvs.org.uk/rcvscouncil20.
Prospective candidates for RCVS Council are welcome to contact the Registrar, Eleanor Ferguson (e.ferguson@rcvs.org.uk) and the RCVS CEO, Lizzie Lockett (l.lockett@rcvs.org.uk) for more information about the role of the College and/or RCVS Council.
RCVS Council will also be holding its next public meeting on Thursday 23 January 2020, prior to the closure date for Council candidate nominations. Prospective candidates are welcome to attend the Council meeting as an observer. Contact Dawn Wiggins, RCVS Council Secretary, on d.wiggins@rcvs.org.uk if you wish to attend.
The case was brought by the College after a member of the public raised a 'concern' relating to Mrs Mullen's practice in December 2015. The concern was not pursued by the College.
However, during its initial investigation, the RCVS case manager ascertained that contrary to the requirements of the Code of Professional Conduct, Mrs Mullen did not have PII.
In January 2016 Mrs Mullen was advised by the College that, in order to comply with the Code, she needed to ensure her professional activities were covered by PII or equivalent arrangements.
The matter was considered by the Preliminary Investigation Committee which asked, in October 2016, that Mrs Mullen produce evidence that she was now compliant with the requirement to have PII or equivalent. Mrs Mullen responded in November 2016 confirming that she had not put in place such arrangements.
The case was then referred to the Disciplinary Committee in January 2017.
During the hearing it was determined that, during the relevant time period (from November 2015 to November 2016) Mrs Mullen was practising but did not have professional indemnity insurance in place and therefore was in breach of the Code.
Mrs Mullen, who represented herself, told the Committee that she admitted that she did not have PII. She explained that she was 'ethically and morally opposed to it' as she felt that it did not give fair compensation to claimants and did not know it was a requirement of the Code of Professional Conduct until she was informed by the College in January 2016.
When giving oral evidence as to equivalent arrangements she disclosed that she kept significant funds in a bank account; these were not however specifically earmarked for use in the event of any possible claims, and were also required to pay practice expenses.
In light of evidence produced by the College and her own admissions, the charges against Mrs Mullen were found proved and she was found guilty of disgraceful conduct in a professional respect.
In coming to this decision Chitra Karve, chairing the Committee and speaking on its behalf, said: "The respondent failed to have PII in place for a period of about 12 months as specified in the charges. Moreover, she failed to remedy the situation when advised in January 2016 by the College that she was in breach of the Code and the supporting guidance. This remains a continuous course of conduct, which has still not been remedied. The respondent has chosen not to read the Code, or the supporting guidance, until very recently, in relation to her obligation to have PII or equivalent arrangements in place, and she failed to heed the advice of the College that she must rectify the position."
In considering the sanction the Committee took into account mitigating and aggravating factors. Aggravating factors included the fact that the misconduct was sustained over a significant period of time and that limited insight was shown by Mrs Mullen. While she did begin to display limited insight into the significance of her misconduct, the Committee said that this insight was "hampered by her ambivalence towards the College and the systems that regulate the veterinary profession."
In mitigation the Committee took into account Mrs Mullen’s long and unblemished career and the fact she was a sole practitioner who reported challenging personal circumstances and provided a unique service to a niche group of clients.
However, Chitra Karve said: "The Committee is unable to overlook the Respondent’s lack of commitment to obtaining PII or equivalent arrangements, even after being advised by the College that this was essential. The Committee is aware that a suspension could adversely affect her practice and her clients that she uniquely serves. However the Committee thinks it is necessary to send a clear message to the respondent and the public, that failure to obtain PII or equivalent arrangements is wholly unacceptable."
She added: "Accordingly, the Committee directs the Registrar to suspend the respondent’s registration for a period of two months. The Committee considers that this period of suspension will give the respondent an opportunity to rectify her breaches of the Code in relation to PII… and to reflect upon her attitude towards the College and the appropriate regulation of the veterinary profession."
Dilaterol is an oral syrup containing 25 mgs/ml clenbuterol hydrochloride, indicated to treat respiratory disease in horses. It causes intense bronchodilation, inhibits histamine release and increases ciliary mucous clearance. It can be used as a frontline or adjuvant therapy.
Dilaterol is administered via food and comes in a 355 ml bottle with a pump dispenser for easy and accurate dosing.
Emma Jennings, Equine Brand Manager at Dechra said: “We are very pleased to have added Dilaterol to our comprehensive range of equine therapies as it is an established and effective treatment for bronchial conditions.
"It is particularly useful in cases of respiratory allergy, bronchospasm and equine asthma and is already regarded as a valuable tool for veterinary professionals."
Dilaterol will be available to order through wholesalers. For more information, visit www.dechra.co.uk.
The company says the two main benefits of the liquid formulation are precise dosing and ease of administration.
Vetmedin oral solution comes with a kg-bodyweight calibrated syringe to make it easy to give the preferred dose of 0.25 mg/kg twice daily to the nearest 0.5 kg bodyweight.
The maximum syringe volume is for a 12 kg dog.
The solution has a sweet taste to make it palatable and Boehringer says it is also ideal for dogs that need dental work but require treatment for their heart disease before general anaesthesia.
These dogs might struggle to eat chewable tablets due to oral discomfort, so a liquid treatment might be a better option.
The company highlights the EPIC1 and PROTECT2 studies which showed that Vetmedin delays the onset of CHF for dogs in the asymptomatic stage of heart disease and improves both the quality and length of life for dogs with MVD and DCM.
Vetmedin oral solution comes as a 50 ml bottle (each bottle lasts a 5 kg dog approximately 30 days), doesn't need to be refrigerated, has an 8-week shelf life once opened, and a 2-year shelf life as packaged.
VetMedin oral solution is now available to order from wholesalers.
The company says that the 20 module medicine programme, covering all of the major body systems of cats and dog, combines the latest thinking in small animal medicine with its world-class learning resources to ensure that delegates’ learning experience online gives the same high-quality learning as the attendance programme.
Improve says it aims to offer a route for veterinary surgeons who don’t have the time to participate in an attendance programme or who work in countries where this type of training is not available, the opportunity to study for a recognised postgraduate qualification.
Delegates signing up for the programme will have a module tutor – an RCVS or ECVIM/ACVIM Small Animal Internal Medicine Diploma holder – and a dedicated programme tutor who works with individual delegates to ensure they are supported throughout the programme.
Improve says the course includes interactive and engaging modules, together with real-life case studies, presentations, written notes, interactive quizzes and exercises.
Dr Alison Babington MRCVS, Business Coordinator at Improve said: "The pressures on veterinary professionals today have never been more intense and many of us struggle to find the work-life balance which is so important for our well-being. Unfortunately, these pressures often preclude many vets from undertaking the type of postgraduate training which could give them additional job satisfaction and enhance both their career prospects and the profitability of their practice.
"It has been our ambition for some time to offer some of our flagship programmes online and, in creating the Distance Learning Small Animal Medicine programme, we drew on the experience of the latest online platforms.
"This new Distance Learning Programme offers a high quality interactive, engaging Small Animal Medicine learning experience which will be fun to study and a far cry from the days of simply reading text online. It will be accessible to vets working anywhere in the world and we’re very proud to be able to offer a high level programme via this learning route."
For more information visit: www.improveinternational.com or ring 01793 759159.
Alstoe is launching Vetergesic Multidose, a 10ml version of the opiate injection, in a new multi-use vial.
Alstoe Technical Director, Dr Ian Ryder said: "In addition to the new vial size the inclusion of a preservative enables Vetergesic Multidose to be used for up to 28 days following its initial use. Also the product is now licensed for intravenous administration."
Vetergesic Multidose should drastically reduce the amount of product wasted by practices using the old, smaller single-use vial.
Alstoe says that supplying Vetergesic in a multi-use vial was one of the first things discussed with the drug originators, Reckitt Benckiser, when it took over the marketing of the product. However, for a large scale medical pharmaceutical manufacturer to consider producing a veterinary product in a different pack and in much smaller production runs than their medical operating scales, the answer is normally no. But in this case, Reckitts gave the project its full support, so in addition to reduced wastage, the inconvenience of snapping glass necks will become a thing of the past.
Please contact Alstoe Ltd for further information at info@alstoe.co.uk or telephone 01347 878606.
The event is being held in the Bath Assembly Rooms, right in the heart of the city, on Thursday 21st and Friday 22nd September 2017.
Organiser Simon Guiton MRCVS said: "The programme is based on current hot topics for veterinary surgeons and nurses. We've got a great line up of speakers, not to mention everything else that Bath has to offer by way of culture, restaurants and shopping. It sure beats Milton Keynes on a wet Friday afternoon!"
The programme for veterinary surgeons is as follows:
Day One
Day Two
Speakers include Emi Barker, Esther Barrett, Kieran Borgeat, Gwen Covey-Crump, Angie Hibbert, Nicola Kulendra, Shasta Lynch, Natasha Mitchell, Kostas Papasouliotis, Anita Patel, Louise O’Dwyer, Denise Prisk, Suzanne Rudd, Claire Woolford and Holly Witchell.
Early bird tickets on sale at £139 +VAT for one day, £249 +VAT for both days until 30th June.
For more information, visit: http://vetcpdcongress.co.uk
The two best research projects were selected on the awards day with Sara Hillyer from the University of Bristol School of Veterinary Sciences winning the £1,000 top prize for her project on vascular endothelial glycocalyx shedding in clinical disease in cats and dogs.
Nicola Mawson from the Royal (Dick) School of Veterinary Studies won the £500 runner-up prize for her project on feline tooth resorptive lesions.
The other four successful candidates were Emily Clark from the University of Nottingham School of Veterinary Medicine & Science, Luca Fortuna from the Royal Veterinary College London, Jessica Lam from the Royal (Dick) School of Veterinary Studies, and Xaquin Castro Dopico from the Royal (Dick) School of Veterinary Studies. Each were awarded £1000 towards their research.
Michelle Townley, Veterinary Advisor and Bursary Co-ordinator at MSD Animal Health said: "We were delighted that we had so many applications this year and again the standard of research and presentation was extremely high. The winning students presented on a very wide range of research areas and selecting just two winners proved extremely hard. It is very encouraging to see such enthusiasm for research in the vets of the future."
Applicants were judged on the quality and clarity of their research project, and their ability to clearly communicate their conclusions.
Applications for the MSD Animal Health Veterinary Student Research Bursary 2018 will be opened early next year. For further information, visit: www.msd-animal-health.co.uk/company-overview/student-research-bursary.aspx
The webinar will cover the entire disease process of MMVD in dogs from pathology to current treatment approaches and future advancements in therapy, and will include the following presentations:
https://us06web.zoom.us/webinar/register/WN_QyfUofLgRG-YsaXQbkT7Tw#/registration
Tim was the principal veterinary surgeon at Nine Mile Veterinary Group in Wokingham, Berkshire, from its opening in 1985. He grew the business from one vet and three staff to 16 vets and 60 staff, before selling to CVS in 2007.
Thereupon he became the National Veterinary Director for CVS, supporting the business as it grew from 200 to 1200 vets and supporting individual vets and practices with management advice and clinical practice.
In more recent times Tim has been working with a peripatetic surgery group.
Tim has worked at Guide Dogs before: between 1987 and 2007, he was a Centre Veterinary Advisor at the charity’s now-closed site in Wokingham.
Tim said: “Guide dogs are fantastic to work with – they are good-natured and easy to handle, and the owners always have the best interests of the dog at heart. Plus, you know you are helping more than someone’s pet, a working dog making a real difference to a person’s life. A guide dog needs to be happy and healthy to fulfil its role. It all adds up to a very different flavour of vet work.
“I am looking forward to being back, but in a more central role with more strategic responsibility. The veterinary world has changed so much, even in the last ten years, and it will be good to draw on my experiences to help Guide Dogs traverse that change.
“It’s important that we keep the healthcare of guide dogs at the top of the priorities list; the dogs have always been at the very core of the charity. It’s crucial that we have solid relationships with veterinary practices, to ensure our dogs receive the greatest care at the best value to the charity."
In addition, less than half of those surveyed knew the correct temperature for vaccine storage, showing there is a lack of knowledge surrounding standard procedures.
Paul Williams, MSD Animal Health UK technical manager for ruminants said: "Failing to maintain the correct fridge storage temperature compromises vaccine effectiveness and consequently animal health.
"In a significant number of farm fridges monitored, the temperature was elevated to 80C for long periods of time, with the maximum fridge temperature recorded being 240C.
"In the worst cases, over 60% of fridges had been at 0 0C or below 0 0C long enough for vital contents to freeze. When the temperature is too high, vaccines become ineffective. If frozen, the vaccine is destroyed.
"This research shows we have work to do in educating customers about how to store vaccines and I encourage all farmers to check their farm fridge temperatures.
"To promote better practice, we’ve launched an awareness campaign called Fridge Check to educate farmers on the importance of storing vaccines correctly.
"The campaign is being promoted by Disease? Not On My Farm!, an initiative helping farmers take a more proactive approach to preventing disease on farm."
To find out more, visit the Disease? Not On My Farm! Facebook and Twitter pages or follow the hashtag #FridgeCheck for more information about how to store vaccines correctly.
Reference
There is a need to raise farmers’ awareness of correct vaccine storage temperatures. Williams P. (MSD Animal Health), Paixao G. (University of Bristol).
Miss Johnson was convicted at North Somerset Magistrates’ Court following a guilty plea of the offence of theft by employee in December 2023, after she stole buprenorphine belonging to Yatton Vets earlier that year.
She was sentenced to a fine of £120, a surcharge of £48, and costs of £85.
There were four further charges against Miss Johnson.
Charge one related to Miss Johnson stealing 5ml of methadone in December 2022 from her employer, Vets4Pets in Bristol, and injecting herself with the methadone.
The police investigated the incident and Miss Johnson accepted a conditional caution for the theft, the condition being she should attend a drug awareness course.
Charge two related to Miss Johnson dishonestly taking a syringe of methadone in August 2023 from her employer, the Langford Small Animal Hospital, and injecting herself with it.
Charge three related to two dates in September 2023 when she dishonestly took methadone, gabapentin and buprenorphine from Yatton Vets, her then employer, injecting herself with the buprenorphine and then working when unfit to do so.
Miss Johnson was later convicted of theft in relation to the buprenorphine (charge five).
Charge four related to an incident in November 2023, when Miss Johnson dishonestly took a syringe of buprenorphine from Bristol PDSA, for the purposes of self-administration, and was dishonest both to other members of staff and in the clinical records about the circumstances of taking the buprenorphine.
Charge five was in relation to Miss Johnson’s criminal conviction.
At the outset of the hearing, Miss Johnson admitted all charges in their entirety.
Having reviewed all the evidence and taken Miss Johnson’s admissions into account, the Committee found each of the charges proved.
After the criminal proceedings had finished and had been reported to the College, Miss Johnson wrote a letter expressing her deepest apologies to both the RCVS and the profession.
Within this she also made it clear that she took full responsibility for her actions.
In a later statement, she added that she had tried to use the experience to learn and improve in every aspect of her career and life and did not want to defend her behaviour.
Within this statement she also retracted a previous request to resign from the register, stating that she would accept any outcome to the investigation.
In deciding whether the proved charges amounted to serious professional misconduct, the Committee took the following aggravating factors into account:
The Committee identified no mitigating factors and concluded that for each of the individual charges Miss Johnson’s conduct fell far short of the conduct expected of a member of the profession and that each of the charges one to four amounted to serious professional misconduct.
In relation to charge five, the criminal conviction, the Committee noted that the nature and the circumstances of the offence involved dishonesty, abuse of her professional position regarding access to controlled drugs, breach of her employer’s trust, and that the misconduct took place notwithstanding an investigation by the police for similar conduct in December 2022.
The Committee therefore concluded that charge five rendered Miss Johnson unfit to practise.
When deciding on a sanction, the Committee took into account mitigating factors, which included:
The Committee found no further aggravating factors at this stage.
Kathryn Peaty, chairing the Committee and speaking on its behalf said: “The Committee considered that the overall misconduct proved so serious and was incompatible with remaining on the register.”
She added: “The Committee accepted that Miss Johnson was currently likely to be drug-free on the basis of her evidence and that of her referee, but it noted that independent testing proving she had been drug free for any period of time was not available to it.
"Furthermore, Miss Johnson had been unable to demonstrate that she had worked without any incident recently as she had accepted she had been dismissed from her recent job.
“Having taken into account all of the aggravating and mitigating factors, and balancing the public interest and the need to uphold and maintain standards within the profession, and having decided that Miss Johnson’s insight was limited, the Committee concluded that the sanction of ‘removal’ was the only proportionate sanction it could impose in this case.
"It also decided that such a sanction maintained public confidence in the veterinary profession, safeguarded animal welfare and protected the public from any future risk of repetition of similar behaviour.
“The Committee therefore directed that the Registrar remove Miss Johnson’s name from the register of veterinary nurses forthwith.”
The survey was sent to all UK veterinary practices on the 25th November with a deadline to respond by the 1st December and received 186 responses, a response rate of 6%.
The survey found that during this period:
Lizzie Lockett, RCVS CEO, said: “Thank you once again to all the practice staff who took the time to complete this survey, it really is very useful for us to have a clear picture of how coronavirus and its restrictions are affecting day-to-day activities, as it has an impact both on our decision-making and policies, and what we can tell others about the impact on the professions, such as the UK and national governments.
"The overall picture from this survey is that, while for most it is not business as usual, veterinary practices and members of the professions are, to an extent, getting used to the disruption and have plans and policies in place to help mitigate the impact of the mosaic of different restrictions across the UK.
"While there is hope on the horizon with the start of the roll-out of coronavirus vaccines, we will continue to review and keep up-to-date our advice and guidance to ensure that you can practise to the best of your abilities, while keeping safe and within the rules.
“Of course, we also recognise the toll that the pandemic has taken on many people’s mental health and wellbeing, and this is reflected in some of the more concerning statistics around the impact that staff absences can have on the rest of the team.
"We also asked practices what might help them manage from a staff mental health and wellbeing point of view, and will take these suggestions into account when planning further support via our Mind Matters Initiative mental health project. In the meantime, we would like to remind those who are feeling stressed or are in distress that there are sources of help available during these difficult times – these can be found at www.vetmindmatters.org/help-links/help-during-covid-19/.”
The full report of the survey is available to view at www.rcvs.org.uk/publications
The BSAVA Guide to the Use of Veterinary Medicines has been developed to help veterinary professionals navigate the regulations, changes and issues that face the profession when it comes to the use of veterinary medicines.
Edited by David Harris and Pam Mosedale, there are three new sections which cover:
The BSAVA also highlights that the law in the UK relating to the use of veterinary medicines will be updated when the VMD completes its review.
In addition changes to the RCVS Code of Conduct concerning under care are due to come into force in September.
This, the Association says, will lead to significant changes in medicines use, as well as legal and ethical dilemmas.
As a result, the new guide includes a section at the beginning of the Guide that will be updated as required and the editors encourage all veterinary professionals to stay up to date with the progress of these reviews.
The new BSAVA Guide to the Use of Veterinary medicines is freely available to all via the BSAVA Library.
The RCVS Disciplinary Committee has agreed to adjourn multiple charges against a County Durham-based veterinary surgeon following her undertakings to request removal from the RCVS Register and never to apply to be restored to it.
At the hearing held yesterday, Silke Birgitt Lindridge was charged with disgraceful conduct in a professional respect in regard to four separate allegations, spanning the period of June 2011 to September 2012 whilst in practice at the Safe Hands Veterinary Group. Two of the allegations related to failures to euthanase or arrange the euthanasia of a cat and a dog and being dishonest and/or misleading about these failures, with their respective owners. The other two allegations related to administering a vaccine (Fevaxyn) which was more than two years past its expiry date to a cat, and failure to provide or take adequate steps to provide promptly all the relevant clinical information to a veterinary practice taking over the responsibility for the treatment of a Labrador Cross.
However, before the Disciplinary Committee had heard evidence in respect of these charges, Mrs Lindridge, who did not attend the hearing, had lodged her application for adjournment on the basis that she would request that the Registrar remove her name from the Register with immediate effect and undertake never to apply to be restored to it. The Disciplinary Committee made no enquiry into the facts of the four charges and emphasised that they had neither been proved against, nor admitted by, the respondent.
Removal from the RCVS Register removes a veterinary surgeon's right to practise in the UK. The respondent informed the RCVS that she had no wish to return to the practice of veterinary surgery in this country. Should she subsequently apply to be restored to the Register, the Disciplinary Committee would resume its consideration of the charges, along with the breach of her undertaking.
The Disciplinary Committee was advised that the views of the animal owners involved had been sought and that all had agreed with the proposed course of action.
Speaking on behalf of the Disciplinary Committee, its Chairman, Professor Peter Lees, said: "Having considered the information before it, the Committee has decided it would not be in the public interest to proceed to a full hearing. It is satisfied that the undertakings offered by the respondent [Mrs Lindridge] protect the welfare of animals and uphold the reputation of the profession."
Professor Lees added: "The undertakings offered by the respondent to request the Registrar to remove her name from the Register with immediate effect and never to make an application for restoration to the Register, go beyond any sanction that this Committee could impose at the conclusion of a contested hearing. It does not consider that it would be proportionate for either party to incur the substantial costs of a contested hearing."
Elanco Companion Animal Health has launched a competition to encourage veterinary professionals to showcase the company's new range of practice support materials for the company's parasiticides, Comfortis and Trifexin.
To enter the competition, you'll first need to order the support materials, which include: waiting room posters, client leaflets and a waiting room leaflet dispenser, modular window hangers, social media artwork and display kits which consist of 19 die-cut colour pieces for waiting room displays. Entry / order forms are available here.
Then create your display and email a digital photograph of it to Elanco before the 29th August 2014.
Matthew Rowe, Senior Brand Manager at Elanco said: "We're asking veterinary practices to use their creativity and imagination when putting up their parasite control displays. Last year's winner, the Animal Health Centre in Torquay, even composed their own song, so the more creative the better!"
The overall winner will win a team celebration worth £1000, and there are £250 Amazon vouchers for 11 regional winners.
For further information contact your local Elanco Companion Animal Health key account manager or email elancocahuk@elanco.com
Kruuse UK has expanded the well-known Buster range of “elizabethan” collars with the introduction of a Buster Comfort Collar. This new design is softer and more flexible and features a soft rubber outer edge for better comfort for the animal and is kinder to its surroundings.
Kruuse says prolonged use can make the edges of strong, rigid plastic collars brittle and ragged, especially with active animals, which is why the Comfort Collar was developed to alleviate this problem in such situations. Manufactured out of environmentally-friendly 100 per cent polypropylene, these collars still feature the quick-fastening system found on the Buster Clic Collar and are fully transparent to allow the animal all-round vision. The Buster Comfort Collars are available in seven sizes ranging from 7.5 to 30cm. For further information, please contact: Andrew Groom, Country Manager, Kruuse UK Ltd. Telephone: +44 (0) 1977 681523. E-mail: andrew.groom@kruuse.com.